SHAREHOLDER ALERT: MoonLake Immunotherapeutics Sued For Securities Fraud by Block & Leviton LLP; December 15 Deadline To Seek To Serve As Lead Plaintiff

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging violations of federal securities laws due to false and misleading statements regarding the company's drug candidate, sonelokimab (SLK) [1][2]. Company Allegations - The lawsuit claims that MoonLake Immunotherapeutics misled investors by promoting SLK as superior to competing monoclonal antibodies, specifically failing to disclose that SLK targeted the same molecules as UCB's BIMZELX and did not demonstrate proven superiority [2]. - Following the announcement of Phase 3 results on September 28, 2025, which indicated that SLK did not match the efficacy of BIMZELX, MoonLake's stock plummeted nearly 90%, resulting in significant investor losses [2]. Legal Proceedings - The lawsuit is filed in the Southern District of New York under the case name Bridgewood v. MoonLake Immunotherapeutics et al., and it represents all individuals who purchased MoonLake common stock between March 10, 2024, and September 29, 2025 [3]. - Investors who acquired MoonLake stock during the specified period may seek to be appointed as lead plaintiffs, with a deadline for such motions set for December 15, 2025 [4].